HomeGuides
Discussions

Discussions

Ask a Question
Back to All

BIOBETTER DATABASE

over 1 year ago by null

Biologics have undoubtedly revolutionized treatment, but there is a downside – cost. The complex manufacturing processes and quality control required to develop safe and effective biopharmaceutical drugs often result in expensive final products. Therefore, there is a large demand for approved biologics that are less costly but therapeutically equivalent.

Given the highly competitive field of biosimilars, many companies are making inroads into biobetters. A biobetter addresses the same targets as existing biopharmaceuticals, and usually through the same mode of action, but aims to provide improvements. "Better" can be achieved by making structural changes to the original biologic, such as chemical modification, amino acid changes or protein fusion.

With the rapid expected growth in the biobetters market, Creative Biolabs believes that our ADCC / CDC enhancement technology has the potential to become a safe and efficient expression tool, which can help accelerate the development and production of biobetter therapeutic antibodies on a flexible commercial scale. Explore more of our: ADCC Enhancement Technology, CDC Enhancement Technology.

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC/CDC-enhanced biobetter antibodies. Our scientists are dedicated to bringing years of valuable therapeutic antibody development experience and expertise to our partner to achieve a meaningful partnership together. With our knowledge of quality control agreements and global regulatory requirements, we can help our partners further their programs with more chance to succeed.

For commercial partners interested in our ADCC/CDC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.

  1. Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.

  2. Become a licensed candidate of our programs.